年龄而非Charlson共病指数可预测医学上无法手术的I期非小细胞肺癌立体定向消融放疗后的死亡
这项单中心回顾性研究纳入2008至2013年接受立体定向消融放疗或大分割放疗的335例医学上无法手术的I期非小细胞肺癌患者,通过病历回顾计算Charlson共病指数(CCI)和年龄校正Charlson共病指数(aCCI),并用Kaplan-Meier法和Cox回归分析预后因素。中位生存4.4年,中位随访4.7年,aCCI 7-12在单因素和多因素分析中均与死亡风险增加相关,而CCI 4-9仅在单因素分析中显著。三种生存模型效果相似,年龄可单独替代aCCI或CCI加年龄,且年龄记录更可靠,因此比Charlson评分更实用。
要点
- aCCI 7-12与死亡风险增加独立相关,多因素HR 2.25(95%CI 1.04-4.84,P=0.04)。
- CCI 4-9仅在单因素分析中与死亡风险增加相关。
- 年龄可单独替代aCCI或CCI加年龄,预后价值相同且更可靠。
核心结论
- 男性、体重下降大于10%和年龄是接受SABR或大分割放疗的医学上无法手术I期NSCLC患者的独立预后因素。
- 年龄可单独与aCCI或CCI加年龄互换使用,具有相同的预后价值,且年龄记录更可靠、更不易出错,因此比Charlson评分更有用。
研究设计与样本
- 单中心回顾性研究,纳入2008至2013年335例医学上无法手术的I期NSCLC患者,接受SABR或大分割放疗(50-60 Gy,分次剂量至少5 Gy或4 Gy)。
- 通过个体病历回顾确定共病和Charlson评分,按CCI(0-1、2-3、4-9)和aCCI分层,用Kaplan-Meier法计算累积生存。
- 测试了3种性别分层Cox回归模型:(1)aCCI合并年龄和共病;(2)年龄和CCI;(3)仅年龄,去除共病。
主要发现
- 中位生存4.4年,中位随访4.7年,中位CCI和aCCI分别为2和5。
- aCCI 7-12患者单因素分析死亡风险增加HR 2.45(95%CI 1.15-5.22,P=0.02),多因素分析(排除年龄作为竞争变量)HR 2.25(95%CI 1.04-4.84,P=0.04)。
- CCI 4-9患者单因素分析死亡风险增加HR 1.57(95%CI 1.30-2.90),但多因素分析不显著。
- 连续或分类变量测试中,三种生存模型效应系数相似。
临床怎么用
- 在医学上无法手术的I期NSCLC患者接受SABR或大分割放疗时,可单独使用年龄进行预后评估,替代aCCI或CCI加年龄。
- 年龄记录更可靠、更不易出错,比Charlson评分更实用。
局限性
- 单中心回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this single institution retrospective study of patients with stage I medically inoperable non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR) we attempt to model overall survival (OS) using initial prognostic variables with specific attention on the Charlson co-morbidity index (CCI). METHODS: Between 2008 and 2013, 335 patients with medically inoperable stage I NSCLC were treated with SABR or hypofractionated radiotherapy (50-60 Gy in at least 5 Gy or 4 Gy fractions respectively) at our institution. Medical comorbidities and Charlson scores were determined by individual chart review. Patients were stratified into 3 groups based on the CCI score (0-1, 2-3, 4-9) and again based on the age-adjusted Charlson Comorbidity score (aCCI). Cumulative survival for each stratum was determined using the Kaplan-Meier method. Non-significant and confounding variables were identified and discounted from survival modeling. 3 sex stratified Cox regression models were tested: (1) aCCI with age and comorbidity combined; (2) age and CCI; (3) age alone, comorbidity removed. RESULTS: The median survival was 4.4 years and the median follow up 4.7 years. The median CCI and aCCI scores were 2 and 5 respectively. Patients with aCCI 7-12 had an increased hazard of death on univariate analysis HR 2.45 (1.15-5.22 95%CI, p = 0.02) and -excluding age as a competing variable- on multivariate analysis HR 2.25 (1.04-4.84 95%CI, p = 0.04). Patients with CCI 4-9 had an increased hazard of death on univariate analysis HR 1.57(1.30-2.90) but not on multivariate analysis. On formalized testing - with either continuous or categorical variables- all three survival models yielded similar coefficients of effect. CONCLUSION: We identify male gender, weight loss greater than 10% and age as independent prognostic factors for patients treated with medically inoperable NSCLC treated with SABR or hypofractionated radiotherapy. Based on our survival models, age alone can be used interchangeably with aCCI or CCI plus age with the same prognostic value. Age is more reliably recorded, less prone to error and therefore a more useful metric than Charlson score in this group of patients.
引用
- Holmes OE, MacRae R, Cook G, et al. Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer. Clin Transl Radiat Oncol. 2017. PMID: 29594215. doi:10.1016/j.ctro.2017.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。